NICE expands access for SMA drug Spinraza
Managed access agreement treatment eligibility criteria extended following review
Read More
Tag: Spinraza
Draft guidelines reject NHS funding for Biogen’s Spinraza
The National Institute for Health and Care Excellence is not recommending NHS use of Biogen’s Spinraza for the rare genetic disorder spinal muscular atrophy (SMA) at this time.
Read More
Five therapies endorsed for use on NHS Scotland
A new treatment option for the very rare condition infantile onset 5q spinal muscular atrophy (type I SMA) is among five medicines that have been endorsed by Scottish cost regulators for use on the NHS.
Read More
Biogen ‘optimistic’ for NHS access to Spinraza
Biogen says it is “optimistic” that patients in England and Wales with a rare spinal disorder will get rapid and broad access to Spinraza via the National Health Service in England and Wales.
Read More
EU clears Biogen’s Spinraza for rare spinal disorder
EU regulators have issued clearance for the first therapy to treat spinal muscular atrophy (SMA), a rare and often fatal genetic disease affecting muscle strength and movement.
Read More
US licenses first drug for rare spinal disorder
US regulators recently approved the first therapy to treat spinal muscular atrophy (SMA), a rare and often fatal genetic disease affecting muscle strength and movement.
Read More
- Sun Pharma’s Unloxcyt now available in US for advanced cutaneous squamous cell carcinoma
- Venner Shipley announces opening of new Bristol office
- AAX Biotech and Vascurie announce new neuro-oncology collaboration
- Nxera Pharma reports positive results from phase 3 insomnia trial in South Korea
- Scottish Medicines Consortium becomes first in UK to adopt new precision gastric cancer treatment
